A Study of BGB-11417 in Participants With Myeloid Malignancies (NCT04771130)

🧪 Interventions in This Study

• BGB-11417 (DRUG)
• Azacitidine (DRUG)
• Posaconazole (DRUG)
• BGB-11417 (DRUG)
• BGB-11417 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (46 Sites)

Showing the first 25 of 46 sites.

• City of Hope National Medical Center — Duarte, California
• Tampa General Hospital — Tampa, Florida
• Upmc Hillman Cancer Center(Univ of Pittsburgh) — Pittsburgh, Pennsylvania
• Md Anderson Cancer Center — Houston, Texas
• Medical College of Wisconsin — Milwaukee, Wisconsin
• Concord Repatriation General Hospital — Concord, New South Wales
• St George Hospital — Kogarah, New South Wales
• Orange Health Hospital — Orange, New South Wales
• Gold Coast University Hospital — Southport, Queensland
• Monash Health — Clayton, Victoria
• St Vincents Hospital Melbourne — Fitzroy, Victoria
• Austin Health — Heidelberg, Victoria
• The Alfred Hospital — Melbourne, Victoria
• Fiona Stanley Hospital — Murdoch, Western Australia
• Linear Clinical Research — Nedlands, Western Australia
• One Clinical Research — Nedlands, Western Australia
• Peking University Peoples Hospital — Beijing, Beijing Municipality
• The First Hospital of Lanzhou University — Lanzhou, Gansu
• Guangdong Provincial Peoples Hospital — Guangzhou, Guangdong
• Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong
• The Second Peoples Hospital of Shenzhen — Shenzhen, Guangdong
• Henan Cancer Hospital — Zhengzhou, Henan
• Union Hospital of Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei
• The First Affiliated Hospital of Soochow University — Suzhou, Jiangsu
• The First Affiliated Hospital of Nanchang University Branch Donghu — Nanchang, Jiangxi

📞 Contact the Study Coordinator

Phone: (877) 828-5568

Email: clinicaltrials@beonemed.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Myeloid Leukemia

• PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
• Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
• Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — Burbank, California
• A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
• A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California

Explore by condition: All Acute Myeloid Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.